Drug intelligence / Profile preview

M-Vax (Hadassah Medical Organization)

Development stage: Unknown
Lead developer: Hadassah Medical Organization
Modality: Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

**M-Vax** is an investigational personalized whole-cell therapeutic cancer vaccine evaluated by Hadassah Medical Organization in patients with metastatic melanoma and epithelial malignancies. The product consists of laboratory-expanded autologous or allogeneic tumor cells that are modified with dinitrophenyl to enhance immunogenicity, irradiated to prevent proliferation, and administered repeatedly to stimulate patient-specific antitumor immune responses against tumor-associated antigens.

Other names: Autologous and Allogeneic Whole Cell Cancer VaccineDNP-modified tumor cell vaccine

Beyond the preview

Go deeper on M-Vax (Hadassah Medical Organization).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M-Vax (Hadassah Medical Organization).

Explore the full profile